Dec 03 2024 18 mins 1
Human rabies cases are fortunately rare in the US. Access to pre- and post-exposure prophylaxis, and domestic animal vaccination programs, drive this public health success. This comes at a financial and human resources cost. Dr. Kyle Weant, clinical assistant professor and an emergency medical clinical pharmacy specialist at the University of South Carolina College of Pharmacy and Dr. Philippe Mentler, senior consulting director, join host Gretchen Brummel to discuss the use of rabies immune globulin and rabies vaccine in patients who have been exposed and provide treatment pearls for frontline pharmacy practioners.
Guest speakers:
Kyle Weant, PharmD, BCPS, BCCCP, FCCP
Clinical Assistant Professor and an Emergency Medical Clinical Pharmacy Specialist
University of South Carolina College of Pharmacy
Philippe Mentler, PharmD, BCPS
Senior Consulting Director
Vizient
Host:
Gretchen Brummel, PharmD, BCPS
Show Notes:
[00:54-01:17] Kyle’s background information
[01:18-03:31] Rabies as a disease
[03:32-05:13] Public Awareness
[05:14-07:06] Options right now for post-exposure prophylaxis
[07:07-10:01] Thoughts on dose rounding
[10:02-10:13] Is rabies immunoglobulin considered an essential medication that everyone should stock in their hospital pharmacy
[10:14-11:30] Who should be administering these drugs? And who's ensuring follow up of these patients?
[11:31-14:31] Potential pitfalls in patient management
[14:32-18:12] What should our frontline pharmacy staff know about post-exposure prophylaxis
Subscribe Today!
